Connect to a lawyer

Interlaw's Danish Firm Mazanti Advises Sunstone on an Investment in STipe

Stay informed with all the latest news and developments at Interlaw and our strategic partners. Read all about our recent cross-border mandates, partner hires, office openings, pro bono and community activities, award wins and other achievements. For all media and press enquiries please email Imogen Lee, Interlaw's International Director of Marketing and Communications.

Mazanti-Andersen Korsø Jensen, Interlaw’s representative firm in Denmark, has advised Sunstone Life Science Ventures (Sunstone) on its investment in biotech company STipe Therapeutics.

Sunstone, an independent European venture capital investment firm founded in 2007, is investing in STipe as part of an international syndicate including Novo Holdings, Arix Bioscience plc and Wellington Partners Life Science V Fund. 

The Mazanti team was led by partner Jakob Mosegaard Larsen (pictured above). He said: ”We are pleased to see that the Danish biotech ecosystem continues to foster strong companies that are able to attract funding from international syndicates of very qualified life science investors.”. 

STipe, founded in 2018 and led by CEO Dr. Claus Elsborg Olesen, has raised €20m in series A financing. STipe is an Aarhus-based biotech company focusing on harnessing the innate immune system to battle cancer and target a range of hematological and solid tumors. The company is developing first in class drugs targeting intracellular protein-protein interactions of the STING Pathway, and its innovative technology has demonstrated that it can significantly increase the sensitivity of the innate immune system to rapidly detect even a small amount of tumor-DNA. 

Sunstone General Partner, Sten Verland, who will join STipe Therapeutics’ Board of Directors, commented: “We are excited about the potential of STipe’s novel technology harnessing the effect of the STING pathway. We look forward to leveraging our experience in this exciting field and working with founders and the other investors to bring STipe’s technology into clinical development”.